特立帕肽治疗对中轴与外周骨骼产生不同效应:MOAT研究结果
研究纳入20例绝经后骨质疏松女性,接受特立帕肽治疗104周,用DXA、QCT和HR-pQCT同时评估中轴与外周骨骼。腰椎和骨盆骨密度升高,而颅骨、上肢和下肢骨矿物含量下降,外周皮质骨密度降低、孔隙率增加。全身骨矿物总量未见变化。
要点
- 特立帕肽治疗104周后腰椎和骨盆骨密度升高,但颅骨、上肢和下肢骨矿物含量下降。
- 腰椎L1-L3体积骨密度升高28.5%,而桡骨和胫骨皮质骨密度及组织矿物密度降低、孔隙率增加。
- 全身骨矿物总量未见变化,结论受影像技术局限、缺乏对照组和样本量小所限。
核心结论
- 特立帕肽对中轴骨和外周骨产生不同效应:中轴骨小梁体积骨密度(L1-L3)改善,但外周皮质骨体积骨密度降低且孔隙率增加,全身骨矿物总量未见变化。
研究设计与样本
- 研究纳入20例绝经后骨质疏松女性(年龄65.4±5.5岁),接受为期104周的特立帕肽治疗,采用DXA、定量计算机断层扫描(QCT)和高分辨率外周定量计算机断层扫描(HR-pQCT)进行影像学评估。
主要发现
- 总腰椎面积骨矿物含量(aBMC)增加11.2%,总腰椎面积骨密度(aBMD)增加8.1%,胸椎次区域aBMD增加7.5%,腰椎aBMC增加23.5%,腰椎aBMD增加11.9%,骨盆aBMC增加9.3%,骨盆aBMD增加4.3%。
- 颅骨aBMC降低5.0%,上肢aBMC降低5.1%,下肢aBMC降低2.9%,下肢aBMD降低2.5%。
- L1-L3体积骨密度(vBMD)增加28.5%,但股骨近端总体vBMD未见变化。
- 桡骨和胫骨皮质vBMD分别降低3.3%和3.4%,组织矿物密度分别降低3.2%和3.8%,孔隙率分别增加21.2%和10.3%。
- 胫骨(而非桡骨)小梁不均匀性增加3.2%、失效载荷增加0.2%,但皮质厚度降低3.1%、面积降低2.9%、孔体积降低1.6%。
局限性
- 作者承认其结论可能具有推测性,并受所用影像技术的技术局限性、缺乏对照组以及研究样本量小的约束。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The central and peripheral skeleton was characterised using imaging techniques during 104 weeks of teriparatide treatment. Teriparatide exerts differential effects on the central and the peripheral skeleton. Overall, we did not observe a change in total body bone mineral. Our conclusions are constrained by the study limitations. INTRODUCTION: Teriparatide stimulates bone formation and resorption and therefore can cause bone gain and loss. We simultaneously characterised the central and peripheral skeleton using imaging techniques to better understand the mechanism of action of teriparatide. METHODS: Postmenopausal, osteoporotic women (n = 20, 65.4 ± 5.5 years) were recruited into a 104-week study of teriparatide. Imaging techniques included DXA, quantitative computed tomography (QCT), and high-resolution peripheral quantitative computed tomography (HR-pQCT). RESULTS: Total lumbar spine areal bone mineral content (aBMC) (+ 11.2%), total lumbar spine areal bone mineral density (aBMD) (+ 8.1%), subregional thoracic spine aBMD (+ 7.5%), lumbar spine aBMC (+ 23.5%), lumbar spine aBMD (+ 11.9%), pelvis aBMC (+ 9.3%), and pelvis aBMD (+ 4.3%) increased. However, skull aBMC (- 5.0%), arms aBMC (- 5.1%), legs aBMC (- 2.9%), and legs aBMD (- 2.5%) decreased. Overall, we did not observe a change in total body bone mineral. Increases in L1-L3 volumetric BMD (vBMD) (+ 28.5%) occurred but there was no change in total proximal femur vBMD. Radius and tibia cortical vBMD (- 3.3 and - 3.4%) and tissue mineral density (- 3.2 and - 3.8%) decreased and there was an increase in porosity (+ 21.2 and + 10.3%). Tibia, but not radius, trabecular inhomogeneity (+ 3.2%), and failure load (+ 0.2%) increased, but cortical thickness (- 3.1%), area (- 2.9%), and pore volume (- 1.6%) decreased. CONCLUSIONS: Teriparatide exerts differential effects on the central and the peripheral skeleton. Central trabecular vBMD (L1-L3) is improved, but there is a concomitant decrease in peripheral cortical vBMD and an increase in porosity. Overall, we did not observe a change in total body bone mineral. We acknowledge that our conclusions may be speculative and are constrained by the technical limitations of the imaging techniques used, the lack of a control group, and the small sample size studied.
引用
- Paggiosi MA, Yang L, Blackwell D, et al. Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. Osteoporos Int. 2018. PMID: 29520607. doi:10.1007/s00198-018-4445-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。